In RA, use of systemic glucocorticoids ≥5 mg/d (prednisolone-equivalent) was linked to MACE at 8.7 y
Annals of Internal Medicine · 2023
DOI: 10.7326/j23-0082 ↗Kurz gefasst
Kommentar in der Zeitschrift Annals of Internal Medicine, 2023. Verfasst von Ami Schattner. Beteiligte Einrichtung: Hebrew University-Hadassah, Jerusalem, Israel (A.S.). Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents.
Abstract (Originalsprache)
SOURCE CITATION: So H, Lam TO, Meng H, et al. Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study. Ann Rheum Dis. 2023;82:1387-1393.37487608.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hebrew University-Hadassah, Jerusalem, Israel (A.S.).
Zitieren
APA
Schattner, A. (2023). In RA, use of systemic glucocorticoids ≥5 mg/d (prednisolone-equivalent) was linked to MACE at 8.7 y. Annals of Internal Medicine. https://doi.org/10.7326/j23-0082
Vancouver
Schattner A. In RA, use of systemic glucocorticoids ≥5 mg/d (prednisolone-equivalent) was linked to MACE at 8.7 y. Annals of Internal Medicine. 2023. doi:10.7326/j23-0082
BibTeX
@article{Schattner2023,
author = {Schattner, Ami},
title = {In RA, use of systemic glucocorticoids ≥5 mg/d (prednisolone-equivalent) was linked to MACE at 8.7 y},
journal = {Annals of Internal Medicine},
year = {2023},
doi = {10.7326/j23-0082}
}
EUVIMED